Evidentiary Standards for Diagnostics: When does a Biomarker become a Diagnostic for Cancer Treatment?

In both community and academic cancer centers there is a rapid adoption of NGS and other multiplex platforms to interrogate the biology of an individual’s tumor. For each individual patient, vast amounts of data are being generated, annotated with identification of “actionable” targets for therapeutic intervention. The level of evidence for these target-directed therapies ranges from […]

Taking Immunotherapy Seriously: New Targets and Combinations

This panel will explore the rapidly evolving immunotherapy space, focusing on the increasing value of combinations such as multiple immunotherapies as well as with chemotherapy and targeted agents. Our exploration of next generation approaches such as new checkpoint targets beyond PD1 and novel cell-based therapies like CAR T-cells will lead to a lively discussion and […]